Analyst Views

GID – CIMB Securities rates the stock as Outperform

Target $1.85 (was $1.90). The broker notes the French Government will pay for a clinical study of the company’s EndoBarrier treatment. This is the second study they have paid for, with the new work not so much about efficacy, but rather an investigation into potential price and reimbursement levels based on patient outcomes versus traditional treatment.

Read More